Skip to content

Study · Randomized controlled trial · n = 40 · 2020

5 results

[Comparison of the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke].

Khabirov FA, Khaibullin TI, Granatov EV, Akhmetova GI, Akhmetzyanov NM

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2020

PMID33449527 (opens in a new tab)DOI10.17116/jnevro202012012211 (opens in a new tab)PepBankPUB-33449527
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients recovering from ischemic stroke, Cortexin had less pronounced NIHSS improvement than Cellex.

    In plain wordsIn patients recovering from ischemic stroke, Cortexin had less neurological improvement than Cellex.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseNIHSS score
    Study

    n = 40

    Comparator
    Cellex
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mg daily · intramuscular · 10 daysAs given in this study (human).

    Measurements

    NIHSS median
    3 score
    Cellex group (first-listed value); IQR 2; 4.5
    NIHSS median
    5 score
    Cortexin group (second-listed value); IQR 2; 7

    Source sentences

    Summary
    A more pronounced positive dynamics of NIHSS: 3 [2; 4.5] vs. 5 [2; 7] (p=0.03) and MMSE scores: 24 [21.5; 25] vs. 22 [20; 23] (p=0.04) was noted in the cellex group.
    3 context sentences
    Summary · context
    To compare the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke (ERPIS) receiving basic therapy (BT).
    Summary · context
    Forty patients were randomized into the cellex group (n=20) and the cortexin group 2 (n=20).
    Summary · context
    Cellex was administered in a dose of 0.1 mg daily SC for 10 days and cortexin in a dose of 10 mg per 2 ml of 0.9% NaCl solution IM daily for 10 days.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients recovering from ischemic stroke, Cortexin had less pronounced MMSE improvement than Cellex.

    In plain wordsIn patients recovering from ischemic stroke, Cortexin had less cognitive improvement than Cellex.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseMMSE score
    Study

    n = 40

    Comparator
    Cellex
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 mg daily · intramuscular · 10 daysAs given in this study (human).

    Measurements

    MMSE median
    24 score
    Cellex group (first-listed value); IQR 21.5; 25
    MMSE median
    22 score
    Cortexin group (second-listed value); IQR 20; 23

    Source sentences

    Summary
    A more pronounced positive dynamics of NIHSS: 3 [2; 4.5] vs. 5 [2; 7] (p=0.03) and MMSE scores: 24 [21.5; 25] vs. 22 [20; 23] (p=0.04) was noted in the cellex group.
    3 context sentences
    Summary · context
    To compare the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke (ERPIS) receiving basic therapy (BT).
    Summary · context
    Forty patients were randomized into the cellex group (n=20) and the cortexin group 2 (n=20).
    Summary · context
    Cellex was administered in a dose of 0.1 mg daily SC for 10 days and cortexin in a dose of 10 mg per 2 ml of 0.9% NaCl solution IM daily for 10 days.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients recovering from ischemic stroke, depressive disorder regression showed a nonsignificant trend favoring Cellex over Cortexin.

    In plain wordsIn patients recovering from ischemic stroke, depression improvement showed a nonsignificant trend favoring Cellex over Cortexin.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    No significant changeDepressive disorder regression
    Study

    n = 40

    Comparator
    Cellex
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    10 mg daily · intramuscular · 10 daysAs given in this study (human).

    Measurements

    BDS median
    17.5 score
    first-listed value; IQR 14.5; 21
    BDS median
    14 score
    second-listed value; IQR 13; 16

    Source sentences

    Summary
    Also, in this group, a more significant trend towards regression of depressive disorders (BDS) was revealed: 17.5 [14.5; 21] vs. 14 [13; 16] (p=0.064).
    3 context sentences
    Summary · context
    To compare the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke (ERPIS) receiving basic therapy (BT).
    Summary · context
    Forty patients were randomized into the cellex group (n=20) and the cortexin group 2 (n=20).
    Summary · context
    Cellex was administered in a dose of 0.1 mg daily SC for 10 days and cortexin in a dose of 10 mg per 2 ml of 0.9% NaCl solution IM daily for 10 days.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients recovering from ischemic stroke, Rivermead Mobility Index changes did not differ significantly between Cortexin and Cellex.

    In plain wordsIn patients recovering from ischemic stroke, mobility score changes did not differ significantly between Cortexin and Cellex.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    No significant changeRivermead Mobility Index change
    Study

    n = 40

    Comparator
    Cellex
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    10 mg daily · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    The dynamics of RMI and FAB scores did not differ significantly between the groups.
    3 context sentences
    Summary · context
    To compare the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke (ERPIS) receiving basic therapy (BT).
    Summary · context
    Forty patients were randomized into the cellex group (n=20) and the cortexin group 2 (n=20).
    Summary · context
    Cellex was administered in a dose of 0.1 mg daily SC for 10 days and cortexin in a dose of 10 mg per 2 ml of 0.9% NaCl solution IM daily for 10 days.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients recovering from ischemic stroke, Frontal Assessment Battery changes did not differ significantly between Cortexin and Cellex.

    In plain wordsIn patients recovering from ischemic stroke, frontal function score changes did not differ significantly between Cortexin and Cellex.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    No significant changeFrontal Assessment Battery change
    Study

    n = 40

    Comparator
    Cellex
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 mg daily · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    The dynamics of RMI and FAB scores did not differ significantly between the groups.
    3 context sentences
    Summary · context
    To compare the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke (ERPIS) receiving basic therapy (BT).
    Summary · context
    Forty patients were randomized into the cellex group (n=20) and the cortexin group 2 (n=20).
    Summary · context
    Cellex was administered in a dose of 0.1 mg daily SC for 10 days and cortexin in a dose of 10 mg per 2 ml of 0.9% NaCl solution IM daily for 10 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.